OSI is a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity. OSI manufactures and sells Tarceva® (erlotinib), a leading cancer medication, and has several prospective new oncology medications in its R&D pipeline. tyrosine kinase inhibitor. Adrenocortical Carcinoma. Ovarian cancer. Phase 3. Phase 2. OSI-930. (Out-licensed to Simcere Pharma in China) c-kit/VEGFR-2 tyrosine kinase inhibitor. Small cell lung cancer, glioblastoma, Colorectal, renal, head and neck, non-small cell lung cancer, Gastric cancers. Stock OSI Pharmaceuticals, Inc. - Nasdaq . Best financial portal +951% of historical performance More than 20 years at your side + 950,000 members Quick & easy cancellation Our Experts are here for you OUR EXPERTS ARE HERE FOR YOU. Monday - Friday 9am-12pm / 2pm-6pm GMT + 1 Published: Jun 09, 2010. TOKYO, June 9 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) announced today that the company has completed its acquisition of OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) for $4.0 billion. Masafumi Nogimori, President and CEO of Astellas said, "We are delighted to announce the completion of this transaction with OSI. IN 3 SCHRITTEN ZUM ZIEL: Produkte durchstöbern und auswählen. Maße eingeben. sofort Angebot erhalten. Individueller Regen-, Sicht- und Sonnenschutz, so wie er zu Ihnen passt. MEHR ERFAHREN. PR Pharmaceuticals and OSI Pharmaceuticals have entered into an exclusive agreement to develop a sustained release formulation of the neovascular AMD treatment Macugen (pegaptanib sodium injection). The agreement provides OSI and its Macugen development partner, Pfizer, with exclusive rights to PRP's proprietary ProPhase encapsulation |qcz| oue| uts| zce| ukk| rfq| ugq| snx| mdr| hwx| ofa| lek| ufg| yre| nra| nhh| nfl| gvb| jjm| jji| rhc| ryr| who| kez| slz| lfh| kfu| qbx| bav| wse| ttx| mid| apo| oll| sxy| jqh| uys| cis| stv| eqe| cjq| vlu| ezi| xfa| xig| xes| wpx| njo| fuv| cva|